ClinicalTrials.gg
RecruitingNCT07408167Updated Nov 17, 2026

AI Models in Clinical Pathology Diagnosis: A Multicenter RCT

An interventional study of AI model and Control in Pathology Foundation Model, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nanfang Hospital, Southern Medical University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,060
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The investigators plan to conduct a multicenter, prospective, randomized controlled trial to systematically evaluate the incremental value of pathology-based artificial intelligence (AI) models in a pan-disease diagnostic workflow. The study will primarily compare interpretation using an AI-assisted platform with conventional independent slide reading in terms of diagnostic accuracy (e.g., AUC), reading efficiency (e.g., diagnostic time), diagnostic report quality, diagnostic confidence (Likert scale), and pathologists' satisfaction with the AI model. Investigators will also assess superiority among less experienced (junior) pathologists and non-inferiority among more experienced (senior) pathologists. Successful completion of this project will provide high-level prospective evidence to support standardized deployment, quality control, and broader implementation of pathology AI in clinical practice. This trial may also evaluate the potential benefits and risks of using AI tools in medical research.

Read the detailed description

In this study, investigators plan to enroll 60 pathologists with varying levels of experience and 2,000 patients requiring pathological diagnosis, with whole-slide images (WSIs) collected.

02

Conditions studied

  • Pathology Foundation Model

Keywords

  • Randomized Controlled Trial
03

In context

Lead sponsor

Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Pathologists:

Inclusion Criteria:

  1. Voluntarily provide written .
  2. Age ≥ 20 years.
  3. Have completed at least 1 year of training in pathological diagnosis.

Exclusion Criteria:

  1. Individuals with reading difficulties or a reading disorder.
  2. Unwilling to participate in this study.

Patients:

Inclusion Criteria:

  1. Voluntarily provide written informed consent.
  2. Age ≥ 18 years.
  3. Have available digital pathology images and relevant clinical information.

Exclusion Criteria:

  1. Missing data or data quality not meeting the requirements for analysis.
  2. Deemed unsuitable for participation by the investigator.
  3. Unwilling to participate in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
2,060 participants (estimated)

Study arms

  • Experimental
    AI-assisted group

    Pathologists in this group are required to use the AI pathology diagnostic model to assist their diagnoses. The AI pathology model will provide a predicted result for each case.

    Other: AI model

  • Placebo comparator
    Independent Diagnosis Group (Control Group)

    In this group, pathologists will independently diagnose each case based on their own clinical experience, and will record both their time to diagnosis and their diagnostic confidence.

    Other: Control

Interventions

  • OtherAI model

    Doctors in this group are required to use the AI model to assist their diagnoses. The AI pathology model will provide a predicted result for each case.

  • OtherControl

    Pathologists will independently diagnose each case based on their own clinical experience, and will record both their time to diagnosis and their diagnostic confidence.

06

What researchers measure

Primary outcomes

  1. Area under ROC curve (AUC)

    Area under the curve

    Time frame: Assessments will be conducted within one week after the pathologists' diagnoses

Secondary outcomes

  1. Diagnostic time per case

    Time required for the pathologist to complete the diagnosis of each case in the AI-assisted diagnosis group compared with the independent diagnosis group. Diagnostic time is defined as the duration (in minutes/seconds) from initiating case review to finalizing and submitting the diagnostic report in the study system.

    Time frame: Measured immediately after the pathologists' diagnosis

  2. Pathologists' diagnostic confidence

    Self-reported diagnostic confidence of pathologists for each case in the AI-assisted diagnosis group compared with the independent diagnosis group. Diagnostic confidence will be rated by the reporting pathologist on a \[10\]-point Likert scale (e.g., 1 = very uncertain to 10 = very confident) immediately after completing the diagnosis. Higher scores indicate greater diagnostic confidence.

    Time frame: At the time of diagnosis for each case.

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • The First Hospital Affiliated to AMU SOUTHWEST HOSPITAL · Chongqing, Chinano status→Not yet recruiting
  • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • The First Hospital Affiliated to AMU SOUTHWEST HOSPITAL · Chongqing, Chinano status→Not yet recruiting
    • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07408167
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Zhengyu Zhang
Contact
zzyusmu@163.com
13837365993
Li Liang
study chair · Nanfang Hospital, Southern Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion